Bactolac Pharmaceutical Inc logo

BTCA - Bactolac Pharmaceutical Inc Share Price

$120000 0.0  0.0%

Last Trade -

Sector
Consumer Defensives
Size
Mid Cap
Market Cap £905.5m
Enterprise Value £907.3m
Revenue £21.1m
Position in Universe th / 6337
Bullish
Bearish
Unlock BTCA Revenue
Momentum
Relative Strength (%)
1m -5.23%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Sep 2000 2001 2002 2003 2004 2005 2006E 2007E CAGR / Avg
16.1 17.6 21.6 12.8 17.6 22.9 +7.4%
+95.5 -56.9
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 June 2006, Bactolac Pharmaceutical Inc. revenues increased 22% to $20.5M. Net income remained flat at $1.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions., offset by Interest, Net increase from $153K to $473K (expense), Other, Net decrease of 48% to $11K (income). Basic Earnings per Share excluding Extraordinary Items increased from $3426.47 to $3763.88.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

BTCA Revenue Unlock BTCA Revenue

Net Income

BTCA Net Income Unlock BTCA Revenue

Normalised EPS

BTCA Normalised EPS Unlock BTCA Revenue

PE Ratio Range

BTCA PE Ratio Range Unlock BTCA Revenue

Dividend Yield Range

BTCA Dividend Yield Range Unlock BTCA Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
BTCA EPS Forecasts Unlock BTCA Revenue
Profile Summary

Bactolac Pharmaceutical, Inc. is a vitamin manufacturer in nutraceutical products and services. The Company is a product development company, which offers packaging solutions, label design and compliance, and shipping strategies. The Company provides vitamins, nutraceuticals and other private label nutritional supplements, including probiotics, resveratrol, multivitamins, nutritional shake powders, acai and antioxidant products, green and berry food powders, sports supplements and creatine, men's sexual enhancement formulas, weight loss and detoxification products, and women's prenatal and hormone supplements. The Company's product offerings include powders, tablets, capsules, soft gel, liquids and packaging. It also offers pet products and herbal supplements. Its packaging service includes blisters, bottles, boxes, gusset bags, inserts, lids, protective closures, labeling, single serve pouches and stick packs.

Directors
Last Annual September 30th, 2005
Last Interim June 30th, 2006
Incorporated February 28, 2000
Public Since July 15, 1994
No. of Shareholders: 2,500
No. of Employees: 125
Sector Consumer Defensives
Industry Food & Tobacco
Index
Exchange OTC Markets Group
Shares in Issue 9,523
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BTCA Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BTCA
Upcoming Events for BTCA
Frequently Asked Questions for Bactolac Pharmaceutical Inc
What is the Bactolac Pharmaceutical Inc share price?

As of , shares in Bactolac Pharmaceutical Inc are trading at $120000, giving the company a market capitalisation of £905.5m. This share price information is delayed by 15 minutes.

How has the Bactolac Pharmaceutical Inc share price performed this year?

Shares in Bactolac Pharmaceutical Inc are currently trading at $120000 and the price has moved by -1.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bactolac Pharmaceutical Inc price has moved by -1.78% over the past year.

What are the analyst and broker recommendations for Bactolac Pharmaceutical Inc?

There are no analysts currently covering Bactolac Pharmaceutical Inc.

When will Bactolac Pharmaceutical Inc next release its financial results?

Bactolac Pharmaceutical Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2007-06-30
What is the Bactolac Pharmaceutical Inc dividend yield?

Bactolac Pharmaceutical Inc does not currently pay a dividend.

Does Bactolac Pharmaceutical Inc pay a dividend?

Bactolac Pharmaceutical Inc does not currently pay a dividend.

When does Bactolac Pharmaceutical Inc next pay dividends?

Bactolac Pharmaceutical Inc does not currently pay a dividend.

How do I buy Bactolac Pharmaceutical Inc shares?

To buy shares in Bactolac Pharmaceutical Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bactolac Pharmaceutical Inc?

Shares in Bactolac Pharmaceutical Inc are currently trading at $120000, giving the company a market capitalisation of £905.5m.

Where are Bactolac Pharmaceutical Inc shares listed? Where are Bactolac Pharmaceutical Inc shares listed?

Here are the trading details for Bactolac Pharmaceutical Inc:

Country of listing: United States
Exchange: OTC
Ticker Symbol: BTCA
What kind of share is Bactolac Pharmaceutical Inc?

We were not able to load our ranking data for Bactolac Pharmaceutical Inc

Is there a Bactolac Pharmaceutical Inc share price forecast 2020?

We were not able to load any forecast data for Bactolac Pharmaceutical Inc.

How can I tell whether the Bactolac Pharmaceutical Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bactolac Pharmaceutical Inc. Over the past six months, the relative strength of its shares against the market has been 6.09%. At the current price of $120000, shares in Bactolac Pharmaceutical Inc are trading at % against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bactolac Pharmaceutical Inc PE Ratio?

The Bactolac Pharmaceutical Inc PE ratio based on its reported earnings over the past 12 months is 30.62. The shares are currently trading at $120000.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Bactolac Pharmaceutical Inc?

Bactolac Pharmaceutical Inc's management team is headed by:

F. Wayne Ballenger - DRC
Gregory Pusey - PRE
Jeffrey McGonegal - SVF
Pailla Reddy - CHM
Randall Humphreys - DRC
David Welch - DRC
Who are the major shareholders of Bactolac Pharmaceutical Inc?

Here are the top five shareholders of Bactolac Pharmaceutical Inc based on the size of their shareholding:

Similar to BTCA
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.